New York-based Formation Bio, an AI-native pharma company focused on accelerating drug development, revealed that its ...

The star of Monday’s deal is gusacitinib, a small-molecule drug that Formation is developing for chronic hand eczema. Sanofi ...

Formation Bio’s subsidiary, Libertas Bio, has licensed gusacitinib, an oral dual JAK/SYK inhibitor, to Sanofi.

Westlake and Ascend close plants, Chemify opens AI-robotics lab, Formation licenses gusacitinib to Sanofi, and more ...

Having secured one of last year’s largest funding rounds, AI-focused Formation Bio is now eyeing up 545 million euros ($626 ...

Formation Bio Licenses Gusacitinib to Sanofi: Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und . FNRD-2.627.0. Wie bewerten Sie die aktuell angezeigte Seite?

This month’s exploration into a pharmaceutical company’s history is the turn of French company Sanofi, which began over 100 years ago as a number of small companies. Sanofi is one of the ...

Sanofi Ventures – focused on early-to-mid stage investing, company co-creation, leading financing rounds, and prioritising those companies advancing innovation – has announced an additional ...

Sanofi India Ltd Summary. Sanofi India Limited, was initially incorporated as Aventis Pharma Limited in May, 1956. The Company changed its name from Aventis Pharma Limited to Sanofi India Limited ...

MONROE COUNTY, Pa. - Sanofi, maker of anti-inflammation drug Dupixent, will report third-quarter earnings Friday before the opening of U.S. markets.